TÜRKÇE

MEDCONCEPT

Home Page

Reference Projects

Services

Distribution

Contact

  • ​

    • Acquisition of Ilsan Iltas

       Initiation, management and finalization of the deal

       Corporate integration to Hexal

       Increase of annual turnover from 55 million USD to 220 million USD (after 4 years)

       Gain of export leadership in Turkey (50% MS)

       Increase from 500 to 1.200 employees (120 people R&D team)

       Establishment of new manufacturing facility

       First FDA approval for a finished dosage form for export to USA from Turkey

       Acquisition and integration of Biokem and Koz to Hexal

       

    • Over 110 registration submissions in 3 years

       

    • Over 20 successful product launches in 2 years

       

    • Management of integration and rebranding to Sandoz in Turkey after the global  acquisition of Hexal by Sandoz/Novartis

  • ​

    • Establishment of Nycomed Turkey start-up within 2 month

       Initiation, management and finalization of the deal

       Corporate integration to Hexal

       Increase of annual turnover from 55 million USD to 220 million USD (after 4 years)

       Gain of export leadership in Turkey (50% MS)

       Increase from 500 to 1.200 employees (120 people R&D team)

       Establishment of new manufacturing facility

       First FDA approval for a finished dosage form for export to USA from Turkey

       Acquisition and integration of Biokem and Koz to Hexal

       

    • Recruitment of 35 HQ team (1st year)

       

    • Sizing & Recruitment of 100 Reps PPI & Pain (1st year)

       

    • Sizing & Recruitment of 70 Reps Respiratory (2nd year)

       Training package (Sales skills, pharmacy negotiation, basic medical & product trainings)

       Territory alignment for the recruited team

       Incentive and performance measurement systems in track with line KPI’S

       Implementation of electronic territory management solution

    • Execution of 2 GMP audits

    • Acquisition of Biomeks (Licenses from 7 licensors with 11 molecules)

    • Respiratory fast track registration

    • Management of Nycomed integration to Takeda after global acquisition

       Assessment of Takeda Turkey and Nycomed Turkey first line managers, Reps etc.

       Evaluation of new portfolio

       Revision and implementation of new compliance guidelines

  • ​

    • Establishment of Apotex Turkey start-up within 6 weeks

       

    • Submission of 43 molecules (> 100 presentations) in 11 month

       

    • Execution of 2 GMP audits (CND and IND)

       

    • Implementation of first umbrella concept in Turkey

    • Recruitment of 15 HQ team

    • Sizing & Recruitment of 28 rep CNS line

    • Sizing & Recruitment of 15 rep cardiology line

       Training package (Sales skills, pharmacy negotiation, basic medical & product trainings)

       Territory alignment for the recruited team

       Incentive and performance measurement systems in track with line KPI’S

       Implementation of own electronic territory management solution